德國Medigene AG拚 癌症免疫療法, 放棄開發微脂體EndoTAG(R)技術 轉移至杏國

獲新藥SB05突破主導權，杏國活力旺 2015年12月18日 09:36 【時報記者郭鴻慧台北報導】 杏國(4192)取得新藥SB05突破主導權，多頭喜出望外，股價跳空開高，晨盤漲幅逼近4%，表現相對強勢。杏國與德國策略夥伴Medigene更換SB05新約，獲得全方位原品項的新適應症、新品項新適應症及新技術新衍生品項等開發權利，而無需支付新成本，此為發展癌症事業新藥市場版圖再添利器。杏國在17日與德國策略夥伴Medigene公司(MG)雙方協議原SB05(EndoTAG-1)帶正電荷微脂體抗癌試驗中新藥全球性臨床試驗與產銷權契約更換新約。杏國在2013年5月27日取得MG股權並獲治療三陰性乳癌試驗新藥EndoTA-1的全球三期臨床試驗研發技術、產銷等授權。由於MG公司目前著重免疫治療領域技術的研發，為避免EndoTA技術平台發展遲滯，並符合杏國與MG各自發展項目重點，提升杏國在帶正電微脂體藥物領域領導地位，經此談判更換新約，杏國獲SB05各期臨床試驗的研發技術、產銷及其他新適應症、平台技術(EndoTA Platform)等全方位應用權利，此外在付款條件變更後將可大幅提升產品商化利益；而MG公司則可在短期內收取依階段支付之技術轉移授權金，並更專注於開發個人化免疫醫療平台，雙方共創雙贏。

Medigene transfers EndoTAG® to SynCore Medigene AG Posted on: 17 Dec 15 Martinsried/Munich, 17 December 2015. Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immunotherapy company focussing on the development of T-cell therapy platforms for the treatment of cancer, and SynCore Biotechnology Co. Ltd., Taiwan, today signed an asset purchase agreement for the complete transfer of EndoTAG ® to SynCore, replacing and terminating the license agreement from May 2013. Within the framework of the agreement and in addition to licensing payments and proceeds from issued Medigene shares totalling EUR 6.3 m already received, Medigene will receive a payment of EUR 5m from SynCore to be paid in five annual instalments. Moreover, Medigene is eligible to milestone payments and royalties for EndoTAG ® -1. The transaction enables Medigene to further focus on its core business of immuno-oncology. The transfer of EndoTAG ® rights (closing) will take place early 2016, when the first instalment will be paid. Therefore, the agreement will have no impact on Medigene's financial guidance for 2015. EndoTAG ® is a composition of neutral and positive lipids. Loaded with the established cytostatic drug Paclitaxel, EndoTAG ® builds the drug candidate EndoTAG ® -1. Contact Medigene AG Julia Hofmann, Dr. Robert Mayer Lochhamer Str. 11 82152 Planegg/Martinsried Germany Tel.: +49 - 89 - 20 00 33 - 33 01 Email: investor@medigene.com